SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer
Cells · 23.10.2023 · 12 (20) · 2509
DOI: 10.3390/cells12202509 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 23.10.2023. Verfasst von Myeong Jin Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06229, Republic of Korea. Hauptthemen laut MEDLINE: Ferroptosis, Pancreatic Neoplasms, Amino Acid Transport Systems, Neutral. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea (NRF), Ministry of Science and ICT (MSIT), Yonsei University College of Medicine.
Abstract (Originalsprache)
Pancreatic cancer is characterized by a poor prognosis, with its five-year survival rate lower than that of any other cancer type. Gemcitabine, a standard treatment for pancreatic cancer, often has poor outcomes for patients as a result of chemoresistance. Therefore, novel therapeutic targets must be identified to overcome gemcitabine resistance. Here, we found that SLC38A5, a glutamine transporter, is more highly overexpressed in gemcitabine-resistant patients than in gemcitabine-sensitive patients. Furthermore, the deletion of SLC38A5 decreased the proliferation and migration of gemcitabine-resistant PDAC cells. We also found that the inhibition of SLC38A5 triggered the ferroptosis signaling pathway via RNA sequencing. Also, silencing SLC38A5 induced mitochondrial dysfunction and reduced glutamine uptake and glutathione (GSH) levels, and downregulated the expressions of GSH-related genes NRF2 and GPX4. The blockade of glutamine uptake negatively modulated the mTOR-SREBP1-SCD1 signaling pathway. Therefore, suppression of SLC38A5 triggers ferroptosis via two pathways that regulate lipid ROS levels. Similarly, we observed that knockdown of SLC38A5 restored gemcitabine sensitivity by hindering tumor growth and metastasis in the orthotopic mouse model. Altogether, our results demonstrate that SLC38A5 could be a novel target to overcome gemcitabine resistance in PDAC therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06229, Republic of Korea.
- Brain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul 03722, Republic of Korea.
- Yonsei University College of Medicine, Seoul 06229, Republic of Korea.
- Department of Surgery, Yonsei University College of Medicine, Seoul 06229, Republic of Korea.
ORCID-Profile: Hyeon Woong Kang, Hyo Jung Kim, Joon Seong Park
Förderung
- National Research Foundation of Korea (NRF)
- Ministry of Science and ICT (MSIT)
- Yonsei University College of Medicine
Zitieren
APA
Kim, M. J., Kim, H. S., Kang, H. W., Lee, D. E., Hong, W. C., Kim, J. H., Kim, M., Cheong, J. H., Kim, H. J., & Park, J. S. (2023). SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer. Cells, 12(20), 2509. https://doi.org/10.3390/cells12202509
Vancouver
Kim MJ, Kim HS, Kang HW, Lee DE, Hong WC, Kim JH, et al. SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer. Cells. 2023;12(20):2509. doi:10.3390/cells12202509
BibTeX
@article{Kim2023,
author = {Kim, Myeong Jin and Kim, Hyung Sun and Kang, Hyeon Woong and Lee, Da Eun and Hong, Woosol Chris and Kim, Ju Hyun and Kim, Minsoo and Cheong, Jae-Ho and Kim, Hyo Jung and Park, Joon Seong},
title = {SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer},
journal = {Cells},
year = {2023},
volume = {12},
number = {20},
pages = {2509},
doi = {10.3390/cells12202509}
}
EUVIMED